Art

J-GLOBAL ID：201902214450426082   Reference number：19A0729037

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403

感受性非T790M EGFR変異を有する進行性非小細胞肺癌におけるアファチニブによるEGFR-TKI再投与の第II相試験: 岡山肺癌研究グループ試験1403【JST・京大機械翻訳】

Author (17)： Oda Naohiro (Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan) ,  Hotta Kastuyuki (Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan) ,  Hotta Kastuyuki (Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Okayama, Japan) ,  Ninomiya Kiichiro (Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan) ,  Minami Daisuke (Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan) ,  Ichihara Eiki (Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan) ,  Murakami Toshi (Department of Respiratory Medicine, Himeji Red Cross Hospital, Himeji, Japan) ,  Murakami Toshi (Department of Respiratory Medicine, Onomichi City Hospital, Onomichi, Japan) ,  Yokoyama Toshihide (Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan) ,  Ichikawa Hirohisa (Department of Respiratory Medicine, KKR Takamatsu Hospital, Takamatsu, Japan) ,  Chikamori Kenichi (Department of Medical Oncology, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan) ,  Takigawa Nagio (Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan) ,  Ochi Nobuaki (Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan) ,  Harita Shingo (Department of Respiratory Medicine, Okayama Saiseikai General Hospital, Okayama, Japan) ,  Harita Shingo (Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan) ,  Maeda Yoshinobu (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan) ,  Kiura Katsuyuki (Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan)
Material： Cancer Chemotherapy and Pharmacology
Volume： 82  Issue： 6  Page： 1031-1038  Publication year： 2018 
JST Material Number： W4134A  ISSN： 1432-0843  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Abstract/Point： The aim of this study was to e...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0729037&from=J-GLOBAL&jstjournalNo=W4134A") }}

Thesaurus term： human ,  Death ,  *administration (biology) ,  Diarrhea ,  *EGF receptor ,  drug therapy ,  confidence interval ,  effectiveness ,  *non-small cell lung cancer ,  *phase 2 study ,  end point ,  tyrosine kinase inhibitor ,  *EGFR-tyrosine kinase inhibitor ,  *Advanced non-small cell lung cancer ,  *Genetic Variation ,  adverse reaction
Semi thesaurus term： *variation(biology) ,  有害事象 , 【Automatic Indexing@JST】

Author keywords (6)： Non-small-cell lung cancer ,  EGFR mutation ,  Afatinib ,  EGFR-TKI ,  Readministration ,  T790M

JST classification (2)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Terms in the title (12)： 感受性 ,  EGFR ,  変異 ,  進行性非小細胞肺癌 ,  アファチニブ ,  EGFR-TKI ,  再投与 ,  第II相試験 ,  岡山 ,  肺癌 ,  研究 ,  グループ試験